Shilpa Medicare Expands European Portfolio with Novel Drug Delivery Approval

Shilpa Medicare Limited has secured European approval for Tadalafil Orodispersible Films, marking another milestone in its innovative drug delivery solutions. The approval comes from the company's Dabaspet, Bengaluru facility (Unit VI), which specializes in manufacturing oral dispersible films and transdermal patches. This achievement follows the company's recent successes with regulatory approvals, including the EU GMP certification for its Telangana facility. The orodispersible film technology offers enhanced patient compliance through rapid dissolution and easier administration, strengthening Shilpa Medicare's position in the European pharmaceutical market.

Source: Market News Ticker